Retinoic acid signaling in growth plate development: receptor-specific effects, antagonist evidence, and pediatric translational considerations.
- 1Department of Paediatrics, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- 2Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Abstract
The growth plate is a spatially organized cartilage structure that drives longitudinal bone growth and is particularly vulnerable to nutritional imbalance, systemic disease, trauma, and drug exposure during childhood. Retinoic acid (RA), the bioactive metabolite of vitamin A, regulates transcription through retinoic acid receptors (RARα, RARβ, and RARγ). Its skeletal effects depend on concentration, developmental timing, tissue context, and receptor subtype. Physiologic RA homeostasis contributes to orderly chondrocyte maturation, whereas excessive or spatially inappropriate signaling can suppress proliferation, alter hypertrophic differentiation and extracellular matrix, and promote premature growth plate senescence or closure in experimental models. This narrative review integrates evidence on RA metabolism, RAR-dependent chondrocyte fate, and experimental RAR antagonists. Model-dependent antagonist effects include concurrent prevention of hedgehog inhibitor-associated closure and early post-injury attenuation of growth inhibition in juvenile mice; prevention during induction is not reversal of established physeal damage. Human zone-specific receptor biology remains insufficiently resolved, and apparently conflicting findings reflect differences in receptor pharmacology, tissue, developmental stage, timing, dose, and endpoint. Pediatric experience with systemic retinoids, including isotretinoin and the RARγ agonist palovarotene, underscores the developmental hazards of pathway modulation. Future studies should prioritize validated human growth plate models, receptor-subtype pharmacology, and longitudinal skeletal monitoring. RAR antagonism remains a preclinical, hypothesis-generating strategy requiring rigorous dose-window and long-term safety evaluation before pediatric clinical investigation.
Related
- The Impact of TOR-S6K-eIF5A Signaling on Translational Control is Key to Plant Root Development
- Nanomaterial-enabled methods for nucleic-acid sensing: biorecognition, transduction, comparative evidence, and translational considerations
- Theoretical Considerations Regarding the Role of Hyperinsulinemia and Insulin/IGF Signaling in Cancer Metabolic Reprogramming: Potential Mechanisms and Therapeutic Vulnerabilities
- Networked control of bone homeostasis: interfacing post-translational modifications with cellular signaling
- Self-Amplifying RNA Vaccines After the First Approvals: Technology, Development Landscape, and Regulatory Science Considerations
BibTeX
@article{xing2026retinoic,
title = {{Retinoic acid signaling in growth plate development: receptor-specific effects, antagonist evidence, and pediatric translational considerations.}},
author = {Yutong Xing and Ruiying Fan and Kaixi Wang and Xinyu Ma and Fan Xuan and Huifeng Zhang},
journal = {Frontiers in endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1962290},
url = {https://europepmc.org/article/MED/42903657},
note = {CC BY},
}
RIS
TY - JOUR
TI - Retinoic acid signaling in growth plate development: receptor-specific effects, antagonist evidence, and pediatric translational considerations.
AU - Yutong Xing
AU - Ruiying Fan
AU - Kaixi Wang
AU - Xinyu Ma
AU - Fan Xuan
AU - Huifeng Zhang
PY - 2026
DA - 2026/10/06
JO - Frontiers in endocrinology
DO - 10.3389/fendo.2026.1962290
UR - https://europepmc.org/article/MED/42903657
AB - The growth plate is a spatially organized cartilage structure that drives longitudinal bone growth and is particularly vulnerable to nutritional imbalance, systemic disease, trauma, and drug exposure during childhood. Retinoic acid (RA), the bioactive metabolite of vitamin A, regulates transcription through retinoic acid receptors (RARα, RARβ, and RARγ). Its skeletal effects depend on concentration, developmental timing, tissue context, and receptor subtype. Physiologic RA homeostasis contributes to orderly chondrocyte maturation, whereas excessive or spatially inappropriate signaling can suppress proliferation, alter hypertrophic differentiation and extracellular matrix, and promote premature growth plate senescence or closure in experimental models. This narrative review integrates evidence on RA metabolism, RAR-dependent chondrocyte fate, and experimental RAR antagonists. Model-dependent antagonist effects include concurrent prevention of hedgehog inhibitor-associated closure and early post-injury attenuation of growth inhibition in juvenile mice; prevention during induction is not reversal of established physeal damage. Human zone-specific receptor biology remains insufficiently resolved, and apparently conflicting findings reflect differences in receptor pharmacology, tissue, developmental stage, timing, dose, and endpoint. Pediatric experience with systemic retinoids, including isotretinoin and the RARγ agonist palovarotene, underscores the developmental hazards of pathway modulation. Future studies should prioritize validated human growth plate models, receptor-subtype pharmacology, and longitudinal skeletal monitoring. RAR antagonism remains a preclinical, hypothesis-generating strategy requiring rigorous dose-window and long-term safety evaluation before pediatric clinical investigation.
SN - 1664-2392
ER -